Skip Ribbon Commands
Skip to main content
Clin Assoc Prof Ng Quan Sing

Clin Assoc Prof Ng Quan Sing

MBBS (London), MRCP (UK), MD (London),

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interest: Head & Neck, Uro-Oncology, Thoracic-Oncology

Clinical Appointments

  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Senior Lecturer


Dr Ng is a Senior Consultant Medical Oncologist at the National Cancer Centre Singapore, sub-specializing in genitourinary, thoracic, head and neck, and nasopharyngeal cancers. He completed his medical training at Imperial College, University of London, and is a member of the Royal College of Physicians in the United Kingdom. 

He is a clinician scientist, and is a current recipient of the National Medical Research Council research grant to develop new drugs for the treatment of cancer. He was awarded the Doctor of Medicine degree by University College London for his research into novel vascular targeting anti-cancer drugs. He is also actively involved in research to develop functional imaging as a biomarker in oncology. He was awarded the Cancer Research UK research fellowship as well as the British Oncological Association Young Investigator Award for his work. His research has been widely published in both oncology and radiology journals. 

He is actively involved in medical education. He is clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore, as well as research mentor to Duke-NUS Medical School students.


  • MBBS 
  • MRCP (UK) 
  • Doctor of Medicine

Professional Appointments and Committee Memberships

  • Senior Consultant, Department of Medical Oncology, National Cancer Centre Singapore 
  • European Society of Medical Oncology, Member, 2009 - present 
  • Royal College of Physicians (United Kingdom), Member, 2003 - present


  • International Cancer Imaging Society Poster Presentation Prize 2014 
  • European Congress of Radiology Best Scientific Paper (Chest) 2007 
  • British Oncological Association Young Investigator Award 2005 
  • Cancer Research UK Fellowship 2005 
  • FECS/AACR/ASCO Fellowship – Methods in Clinical Cancer Research Workshop 2005 
  • SingHealth Service Quality Award (Silver) 2011

Research Interests

  • Clinical trials of novel therapeutics in all tumour types, with special interests in lung cancers, urological cancers, head and neck cancers, and nasopharyngeal cancer 
  • Early phase clinical trials incorporating multimodality, multi-parametric functional imaging as predictive and prognostic biomarkers


  • Rajasekaran T, Ng QS, Tan DS, Lim WT, Ang MK, Toh CK, Chowbay B, Kanesvaran R, Tan EH. Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett. 2017 Mar 1;388:328-333. doi: 10.1016/j.canlet.2016.12.013. Epub 2016 Dec 18. 
  • Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Chowbay B. J Thorac Oncol. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. 2016 Nov 28. pii: S1556-0864(16)33533-X. doi: 10.1016/j.jtho.2016.11.2225. 
  • Rajasekaran T, Ng QS, Tan DS, Lim WT, Ang MK, Toh CK, Chowbay B, Kanesvaran R, Tan EH. Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett. 2016 Dec 18;388:328-333. doi: 10.1016/j.canlet.2016.12.013. 
  • Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in com Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma bination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2016 Sep 28. pii: mdw415 
  • Sutiman N, Zhang Z, Tan EH, Ang MK, Tan SD, Toh CK, Ng QS, Chowbay B, Lim WT. Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules. PLoS One. 2016 May 2;11(5):e0154316. doi: 10.1371/journal.pone.0154316 
  • Tan WL, Tan EH, Lim DW, Ng QS, Tan DS, Jain A, Ang MK. Advances in systemic treatment for nasopharyngeal carcinoma. Chin Clin Oncol. 2016 Apr;5(2):21. doi: 10.21037/cco.2016.03.03. 
  • Ching BC, Tan HS, Tan PH, Toh CK, Kanesvaran R, Ng QS, Tan MH. Differential radiologic characteristics of renal tumours on multiphasic computed tomography. Singapore Med J. 2016 Apr 19. doi: 10.11622/smedj.2016081. 
  • Cheng JJ, Li H, Tan HS, Tan PH, Ng LG, Ng QS, Toh CK, Kanesvaran R, Tan MH. Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 Apr;14(2):168-75. doi:10.1016/j.clgc.2015.12.012

Research Trials

  • A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC), 2016